CareDx, Inc (NASDAQ:CDNA) Shares Sold by Jacobs Levy Equity Management Inc.

Jacobs Levy Equity Management Inc. lessened its holdings in shares of CareDx, Inc (NASDAQ:CDNA) by 30.8% in the third quarter, according to its most recent filing with the SEC. The firm owned 814,716 shares of the company’s stock after selling 363,324 shares during the quarter. Jacobs Levy Equity Management Inc. owned about 1.52% of CareDx worth $25,440,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the business. Royce & Associates LP lifted its holdings in CareDx by 0.3% in the third quarter. Royce & Associates LP now owns 393,286 shares of the company’s stock worth $12,280,000 after purchasing an additional 1,000 shares during the period. Quest Partners LLC raised its position in shares of CareDx by 37.8% during the 3rd quarter. Quest Partners LLC now owns 5,611 shares of the company’s stock worth $175,000 after buying an additional 1,540 shares in the last quarter. Harvest Fund Management Co. Ltd acquired a new stake in shares of CareDx in the 3rd quarter worth approximately $52,000. ClariVest Asset Management LLC boosted its holdings in shares of CareDx by 2.9% in the second quarter. ClariVest Asset Management LLC now owns 64,027 shares of the company’s stock valued at $994,000 after acquiring an additional 1,810 shares in the last quarter. Finally, GAMMA Investing LLC increased its stake in shares of CareDx by 1,021.8% during the second quarter. GAMMA Investing LLC now owns 2,210 shares of the company’s stock valued at $34,000 after acquiring an additional 2,013 shares during the period.

CareDx Trading Down 2.7 %

Shares of CDNA opened at $24.96 on Wednesday. CareDx, Inc has a 1-year low of $7.42 and a 1-year high of $34.84. The stock has a market capitalization of $1.34 billion, a P/E ratio of -9.24 and a beta of 1.84. The business’s 50-day moving average price is $25.44 and its 200 day moving average price is $22.74.

CareDx (NASDAQ:CDNA) last released its earnings results on Monday, November 4th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.11. The business had revenue of $82.88 million for the quarter, compared to the consensus estimate of $80.04 million. CareDx had a negative net margin of 45.90% and a negative return on equity of 53.70%. The firm’s quarterly revenue was up 23.4% compared to the same quarter last year. During the same period last year, the firm posted ($0.43) earnings per share. On average, research analysts predict that CareDx, Inc will post -0.7 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on CDNA shares. The Goldman Sachs Group upped their target price on CareDx from $26.00 to $35.00 and gave the stock a “buy” rating in a research report on Wednesday, October 16th. BTIG Research cut their price objective on CareDx from $40.00 to $35.00 and set a “buy” rating for the company in a report on Tuesday, November 5th. HC Wainwright reiterated a “neutral” rating on shares of CareDx in a research report on Tuesday, October 22nd. Wells Fargo & Company initiated coverage on shares of CareDx in a report on Tuesday, August 27th. They issued an “underweight” rating and a $28.00 price target for the company. Finally, StockNews.com upgraded shares of CareDx from a “hold” rating to a “buy” rating in a report on Thursday, October 17th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, CareDx currently has a consensus rating of “Moderate Buy” and an average target price of $29.60.

Insider Buying and Selling at CareDx

In other CareDx news, Director Peter Maag sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $25.00, for a total transaction of $125,000.00. Following the completion of the sale, the director now directly owns 330,024 shares in the company, valued at approximately $8,250,600. This trade represents a 1.49 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 4.90% of the company’s stock.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.